| Species : |
Human |
| Source : |
Mammalian Cells |
| Tag : |
His |
| Protein Length : |
17-539 a.a. |
| Description : |
LRFN3 is anapproximately 90 kDa member of the Lrfn family of type I transmembraneglycoproteins. Human LRFN3 is synthesized as a 628 amino acid (aa) precursorthat contains a 16 aa signal sequence, a 523 aa extracellular domain (ECD), a21 aa transmembrane region, and a 68 aa cytoplasmic region. The ECD consistsof six leucinerich repeats (LRR), an IgC2like domain, and a fibronectintypeIII domain, tandemly aligned in that order. |
| Form : |
Lyophilized from a0.2 μm filtered solution in PBS. |
| N-terminalSequence : |
Ser17 |
| MolecularWeight : |
56.3 kDa |
| Activity : |
Measured by theability of the immobilized protein to support the adhesion of Neuro2a mouseneuroblastoma cells (ATCC: CCL131). When 5 x 104 cells/well are added torhSALM4 coated plates (2.5 μg/mL, 100 μL/well), approximately 50% 70% willadhere after 30 minutes at 37 °C. Optimal dilutions should be determined byeach laboratory for each application. |
| Endotoxin Level : |
<1.0 EU per 1 μgof the protein by the LAL method. |
| Purity : |
>90%, by SDSPAGE underreducing conditions and visualized by silver stain. |
| Reconstitution : |
Reconstitute at 200μg/mL in PBS. |
| Storage : |
Use amanual defrost freezer and avoid repeated freezethaw cycles. 12 months from date of receipt, -20 to -70°C as supplied.1 month, 2 to 8 °C under sterile conditions after reconstitution. 3months, -20 to -70°C under sterile conditions after reconstitution. |